Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients

被引:79
|
作者
Fujiki, Youhei [1 ]
Kotani, Takuya [1 ]
Isoda, Kentaro [2 ]
Ishida, Takaaki [1 ]
Shoda, Takeshi [2 ]
Yoshida, Shuzo [1 ]
Takeuchi, Tohru [1 ]
Makino, Shigeki [1 ]
机构
[1] Osaka Med Coll, Dept Internal Med 4, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan
[2] Yodogawa Christians Hosp, Dept Rheumatol, Internal Med, Osaka, Japan
关键词
Dermatomyositis; interstitial pneumonia; prognosis; LUNG-DISEASE; AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; POLYMYOSITIS/DERMATOMYOSITIS; COMPLICATION; MYOSITIS; HRCT;
D O I
10.1080/14397595.2017.1318468
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: We retrospectively investigated clinical prognostic factors for interstitial pneumonia (IP) in anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive dermatomyositis (DM) patients. Methods: Subjects comprised 18 patients with anti-MDA5 Ab-positive DM-IP (9 survivors; 9 deaths). Results: Initial serum albumin levels, ferritin levels, and ground-glass opacity (GGO) scores in the right middle lobes were significantly higher in the death group than in the survivor group (p = .033, .013, and .005, respectively). Initial alveolar-arterial oxygen gradient (P[A-a]O-2) was also higher in the death group than in the survivor group (p = .064). Initial serum ferritin, P[A-a]O-2, and right middle lobe GGO score were found to significantly relate to death. Survival rates after 24 weeks were significantly lower among patients with an initial ferritin level of >= 450 ng/mL (25%), P[A-a]O-2 of >= 30 mmHg (31%), and a right middle lobe GGO score of >= 2 (11%) than each of the others (p = .006, .020, and .002, respectively). Conclusions: An initial serum ferritin level of >= 450 ng/mL, P[A-a]O-2 of >= 30 mmHg, and right middle lobe GGO score of >= 2 (GGO >= 5% of the lobe) were identified as poor prognostic factors for anti-MDA5 Ab-positive DM-IP patients.
引用
收藏
页码:133 / 140
页数:8
相关论文
共 50 条
  • [1] Prognostic evaluation of serum osteopontin in patients with anti-MDA5 antibody-positive dermatomyositis associated interstitial lung disease
    Gao, Yujuan
    Zhao, Qi
    Xie, Miaomiao
    Yan, Xin
    Li, Yan
    Zhang, Xin
    Wu, Hongyan
    Dai, Jinghong
    Cao, Min
    Cai, Hourong
    CYTOKINE, 2020, 135
  • [2] Prognostic Evaluation of Serum Osteopontin in Patients with Anti-MDA5 Antibody-Positive Dermatomyositis Associated Interstitial Lung Disease
    Gao, Y.
    Zhao, Q.
    Xie, M.
    Zhang, X.
    Wu, H.
    Cai, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [3] Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress
    Xin Lu
    Qinglin Peng
    Guochun Wang
    Nature Reviews Rheumatology, 2024, 20 (1) : 48 - 62
  • [4] Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress
    Lu, Xin
    Peng, Qinglin
    Wang, Guochun
    NATURE REVIEWS RHEUMATOLOGY, 2024, 20 (01) : 48 - 62
  • [5] New therapies in anti-MDA5 antibody-positive dermatomyositis
    Yasui, Masahiro
    Iwamoto, Taro
    Furuta, Shunsuke
    CURRENT OPINION IN RHEUMATOLOGY, 2024, 36 (01) : 61 - 68
  • [6] Evaluation of Prognostic Factors in Anti-MDA5 Antibody-Positive Patients in Chongqing, China: A Retrospective Study
    Zhou, Jun
    Huang, Wenhan
    Ren, Feifeng
    Luo, Lei
    Huang, Dongmei
    Tang, Lin
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 4775 - 4781
  • [7] Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
    Gono, Takahisa
    Sato, Shinji
    Kawaguchi, Yasushi
    Kuwana, Masataka
    Hanaoka, Masanori
    Katsumata, Yasuhiro
    Takagi, Kae
    Baba, Sayumi
    Okamoto, Yuko
    Ota, Yuko
    Yamanaka, Hisashi
    RHEUMATOLOGY, 2012, 51 (09) : 1563 - 1570
  • [8] Clinical characteristics of anti-MDA5 antibody-positive interstitial lung disease
    Kaenmuang, Punchalee
    Navasakulpong, Asma
    RESPIROLOGY CASE REPORTS, 2021, 9 (01):
  • [9] Anti-MDA5 Antibody-Positive Interstitial Pneumonia with Autoimmune Features Presenting as Amyopathic Hypodermatitic Dermatomyositis: A Case Report
    Mihailescu, Maria L.
    Edens, Cuoghi
    Hoffman, Mark D.
    CASE REPORTS IN DERMATOLOGY, 2021, 13 (01): : 222 - 229
  • [10] Assessing Time of Onset for Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Dermatomyositis
    Lin, Rachel R.
    Warp, Peyton V.
    Maderal, Andrea D.
    Elman, Scott A.
    JAMA DERMATOLOGY, 2024, 160 (05) : 575 - 577